Global Kidney Cancer Drugs Market by Branded Drugs, Clinical Pipeline, Growth Trends and Forecast to 2020, New Report by iHealthcareAnalyst, Inc.
Kidney Cancer Drugs Market by Branded Drug Type – Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), Clinical Phase 1, 2 and 3 Drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) Pipeline Analysis 2016-2020
Maryland Heights, MO, March 23, 2017 --(PR.com)-- The global kidney cancer drugs market to reach nearly USD 5.2 Billion in 2020.
Browse Kidney Cancer Drugs Market by Branded Drug Type – Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), Clinical Phase 1, 2 and 3 Drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) Pipeline Analysis 2016-2020 at https://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/
Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers. They can often shrink or slow the growth of the cancer for a time, but it doesn’t seem that any of these drugs can actually cure kidney cancer. Kidneys serve as natural blood filters, removing the water soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Several targeted drugs can be used to treat advanced kidney cancer. These drugs block angiogenesis (growth of the new blood vessels that nourish cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive.
The global kidney cancer drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (brand) such as Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib), clinical phase 1, 2 and 3 drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) pipeline analysis, and forecasts growth trends (CAGR% - 2016 to 2020). The global kidney cancer drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global kidney cancer drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global kidney cancer drugs market and included in this report are Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Kidney Cancer Drugs Market by Branded Drug Type – Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), Clinical Phase 1, 2 and 3 Drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) Pipeline Analysis 2016-2020 at https://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/
Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers. They can often shrink or slow the growth of the cancer for a time, but it doesn’t seem that any of these drugs can actually cure kidney cancer. Kidneys serve as natural blood filters, removing the water soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Several targeted drugs can be used to treat advanced kidney cancer. These drugs block angiogenesis (growth of the new blood vessels that nourish cancers) or important proteins in cancer cells (called tyrosine kinases) that help them grow and survive.
The global kidney cancer drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (brand) such as Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib), clinical phase 1, 2 and 3 drugs (AGS-003, Cabozantinib, Dovitinib, Keytruda, Opdivo) pipeline analysis, and forecasts growth trends (CAGR% - 2016 to 2020). The global kidney cancer drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global kidney cancer drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global kidney cancer drugs market and included in this report are Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/kidney-cancer-drugs-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories